KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Retained Earnings: 2011-2024

Historic Retained Earnings for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $556.4 million.

  • Supernus Pharmaceuticals' Retained Earnings fell 3.53% to $522.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $522.0 million, marking a year-over-year decrease of 3.53%. This contributed to the annual value of $556.4 million for FY2024, which is 15.31% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Retained Earnings of $556.4 million as of FY2024, which was up 15.31% from $482.6 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Retained Earnings registered a high of $556.4 million during FY2024, and its lowest value of $326.5 million during FY2020.
  • Over the past 3 years, Supernus Pharmaceuticals' median Retained Earnings value was $482.6 million (recorded in 2023), while the average stood at $506.7 million.
  • Data for Supernus Pharmaceuticals' Retained Earnings shows a peak YoY surged of 63.62% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Retained Earnings stood at $326.5 million in 2020, then increased by 16.36% to $379.9 million in 2021, then climbed by 26.67% to $481.2 million in 2022, then grew by 0.27% to $482.6 million in 2023, then rose by 15.31% to $556.4 million in 2024.